These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 26816081)
1. D-SAL and NAP: Two Peptides Sharing a SIP Domain. Gozes I; Sragovich S; Schirer Y; Idan-Feldman A J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081 [TBL] [Abstract][Full Text] [Related]
2. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Shiryaev N; Pikman R; Giladi E; Gozes I Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979 [TBL] [Abstract][Full Text] [Related]
3. A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP. Ivashko-Pachima Y; Gozes I Front Cell Neurosci; 2019; 13():435. PubMed ID: 31632241 [TBL] [Abstract][Full Text] [Related]
4. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Ivashko-Pachima Y; Sayas CL; Malishkevich A; Gozes I Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743 [TBL] [Abstract][Full Text] [Related]
5. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Oz S; Kapitansky O; Ivashco-Pachima Y; Malishkevich A; Giladi E; Skalka N; Rosin-Arbesfeld R; Mittelman L; Segev O; Hirsch JA; Gozes I Mol Psychiatry; 2014 Oct; 19(10):1115-24. PubMed ID: 25178163 [TBL] [Abstract][Full Text] [Related]
6. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). Gozes I; Divinski I; Piltzer I BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S3. PubMed ID: 19091000 [TBL] [Abstract][Full Text] [Related]
7. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. Ivashko-Pachima Y; Gozes I Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats. Kumral A; Yesilirmak DC; Sonmez U; Baskin H; Tugyan K; Yilmaz O; Genc S; Gokmen N; Genc K; Duman N; Ozkan H Brain Res; 2006 Oct; 1115(1):169-78. PubMed ID: 16938277 [TBL] [Abstract][Full Text] [Related]
9. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Amram N; Hacohen-Kleiman G; Sragovich S; Malishkevich A; Katz J; Touloumi O; Lagoudaki R; Grigoriadis NC; Giladi E; Yeheskel A; Pasmanik-Chor M; Jouroukhin Y; Gozes I Mol Psychiatry; 2016 Oct; 21(10):1467-76. PubMed ID: 26782054 [TBL] [Abstract][Full Text] [Related]
10. Prevention of learning deficit in a Down syndrome model. Incerti M; Toso L; Vink J; Roberson R; Nold C; Abebe D; Spong CY Obstet Gynecol; 2011 Feb; 117(2 Pt 1):354-361. PubMed ID: 21252750 [TBL] [Abstract][Full Text] [Related]
11. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Vaisburd S; Shemer Z; Yeheskel A; Giladi E; Gozes I Sci Rep; 2015 Nov; 5():16300. PubMed ID: 26553741 [TBL] [Abstract][Full Text] [Related]
12. VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive Sragovich S; Amram N; Yeheskel A; Gozes I Front Cell Neurosci; 2019; 13():589. PubMed ID: 31992971 [TBL] [Abstract][Full Text] [Related]
13. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. Gozes I; Giladi E; Pinhasov A; Bardea A; Brenneman DE J Pharmacol Exp Ther; 2000 Jun; 293(3):1091-8. PubMed ID: 10869414 [TBL] [Abstract][Full Text] [Related]
14. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. Holtser-Cochav M; Divinski I; Gozes I J Mol Neurosci; 2006; 28(3):303-7. PubMed ID: 16691018 [TBL] [Abstract][Full Text] [Related]
15. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors. Vink J; Incerti M; Toso L; Roberson R; Abebe D; Spong CY Am J Obstet Gynecol; 2009 May; 200(5):524.e1-4. PubMed ID: 19327737 [TBL] [Abstract][Full Text] [Related]
16. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. Smith-Swintosky VL; Gozes I; Brenneman DE; D'Andrea MR; Plata-Salaman CR J Mol Neurosci; 2005; 25(3):225-38. PubMed ID: 15800376 [TBL] [Abstract][Full Text] [Related]
17. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. Oz S; Ivashko-Pachima Y; Gozes I PLoS One; 2012; 7(12):e51458. PubMed ID: 23272107 [TBL] [Abstract][Full Text] [Related]
18. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Sari Y; Gozes I Brain Res Rev; 2006 Aug; 52(1):107-18. PubMed ID: 16488478 [TBL] [Abstract][Full Text] [Related]
19. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Idan-Feldman A; Schirer Y; Polyzoidou E; Touloumi O; Lagoudaki R; Grigoriadis NC; Gozes I Neurobiol Dis; 2011 Dec; 44(3):327-39. PubMed ID: 21827858 [TBL] [Abstract][Full Text] [Related]
20. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Magen I; Gozes I Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]